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In Indian traditional medicine, Boerhaavia diﬀusa (punarnava) roots have been widely used for the treatment of dyspepsia,
jaundice, enlargement of spleen, abdominal pain and as an anti-stress agent. Pharmacological evaluation of the crude ethanolic
extract of B. diﬀusa roots has been shown to possess antiproliferative and immunomodulatory properties. The extract of B. diﬀusa
was studied for anti-proliferative eﬀects on the growth of HeLa cells and for its eﬀect on cell cycle. Bio-assays of extracts from
B. diﬀusa root showed that a methanol:chloroform fraction (BDF 5) had an antiproliferative eﬀect on HeLa cells. After 48h
of exposure, this fraction at a concentration of 200μgmL −1 signiﬁcantly reduced cell proliferation with visible morphological
changes in HeLa cells. Cell cycle analysis suggests that antiproliferative eﬀect of BDF 5 could be due to inhibition of DNA synthesis
in S-phase of cell cycle in HeLa cells, whereas no signiﬁcant change in cell cycle was detected in control cells. The fraction BDF 5
caused cell death via apoptosis as evident from DNA fragmentation and caspase-9 activation. Thus the extract has potential to be
evaluated in detail to assess the molecular mechanism-mediated anticancer activities of this plant.
1.Introduction
Cervical cancer is the most common cancer among women
in several regions of India [1]. Of the 500000 new cases of
cervical cancer reported worldwide annually, India accounts
for one-ﬁfth in terms of overall incidence [2]. Natural
products are the most consistently successful source of
pharmacologically active compounds in which plant mate-
rials deserves an important position. Boerhaavia diﬀusa L.
(Nyctaginaceae), commonly known as “punarnava” in the
Indian system of medicine, is a perennial creeping herb
found abundantly all over India. In old Indian books of
medicine such as the Charaka Samhita and Sushrita Samhita,
it is mentioned that the Ayurvedic preparations made
from punarnava—namely, punarnavastaka kvath, punarnava
kshar and punarnava taila—were used for the treatment of
various ailments [3]. In Indian traditional medicine, roots
of B. diﬀusa have been widely used for the treatment of
dyspepsia, jaundice, enlargement of spleen, abdominal pain
and as an anti-stress agent [4, 5]. Pharmacological studies
have demonstrated that punarnava possesses punarnavoside,
which exhibits a wide range of properties—diuretic [6],
antiﬁbrinolytic [7], anticonvulsant [8], antibacterial [9].
Scientiﬁc studies using the extract of this plant showed
that it has got analgesic and anti-inﬂammatory property
[10, 11], hepato-protective activity [12, 13], immunomodu-
latory activity [14–16] and anti-proliferative properties [17].
Liriodendrin isolated from the methanol extract of the roots
of B. diﬀusa was found to exhibit signiﬁcant calcium channel
antagonistic activity [18]. Similarly, methanol extract also
exhibited a signiﬁcant spasmolytic activity in the guinea
pig ileum, through a direct eﬀect on the smooth muscle
[19]. The aqueous methanol (3:7) extract of B. diﬀusa was
found to be eﬀective in reducing the metastasis formation
by B16F10 melanoma cells [20]. Punarnavine, an alkaloid
from B. diﬀusa could enhance the immune response against
metastatic progression of B16F-10 melanoma cells in mice
[21]. Eupalitin-3-O–β-d-galactopyranoside (Bd-1) isolated
and puriﬁed from the ethanolic leaf extract of B. diﬀusa
shows selective immunosuppressive activity [22]. Whole-
plant extract of B. diﬀusa has radioprotective eﬀect [23].
Two rotenoids isolated from B. diﬀusa, boeravinones G and
H, have been found to potently inhibit the drug eﬄux
activity of breast cancer resistance protein (BCRP/ABCG2),2 Evidence-Based Complementary and Alternative Medicine
a multidrug transporter responsible for cancer cell resistance
tochemotherapy[24].Mostofthesestudieswereeitherdone
with crude extract of the plant or with some known isolated
compounds. In order to isolate novel lead/active principal
from B. diﬀusa, we wanted to explore its antiproliferative
action on cervical cancer. So far there is no such report for
this plant showing its eﬀect on cervical cancer. Investigations
on the chemical constituents of the plant have indicated
the occurrence of several rotenoids namely boeravinone A-J
[24–28] and two alkaloids, Punarnavine-1 and Punarnavine-
2, belonging to the group quinolizidine [29]. Though the
compound from the roots, seeds and leaves of B. diﬀusa,
isolation of β-sitosterol, β-sitosterol-β-d-glucoside, tetra-
cosanoic, hexacosanoic, stearic, palmitic, arachidic acids,
hextriacantane, urosolic acid has been reported [7, 30];
however, it is not known if any of these compounds have
antiproliferative and cytotoxic activity. In spite of various
therapeutic eﬀects of B. diﬀusa, little is known about the
antiproliferative action of root extract of the plant and
its detailed mechanism of action. This prompted us to
investigate the growth inhibitory eﬀect of this plant on
cervical cancer cell line.
2. Methods
2.1.PlantMaterialandExtractionProcedures. Herb B.diﬀusa
was collected from Gwalior, India, in the month of June
2004, and identiﬁed by Dr Gurcharan Singh, Department of
Botany, Sri Guru Teg Bahadur Khalsa College, University of
Delhi, Delhi. The dried roots of this plant were cut into small
pieces and ground into powder. The powder (110g) was
macerated with ether (1L) and allowed to stand for about
24h at room temperature. There after the percolate was
collectedandtheprocessofextractionwasrepeatedsixtimes.
After removing the ether extract, the residue was macerated
with 95% ethanol (1L) followed by water (1l), each for
six times. The extracts were ﬁltered before evaporating to
dryness under reduced pressure at 45◦Cw i t haR o t a r y
evaporator. The percentage yield of the crude extracts was
calculated as: (weight of crude extract/weight of fresh plant)
× 100%.
2.2. Bioactivity-Guided Puriﬁcation. All extracts obtained
from three diﬀerent extraction solvents (ether, ethanol and
water) were subjected to cell proliferation assay. From the
bioassay results ethanolic extract, which showed signiﬁcant
inhibitory eﬀect was further subjected for puriﬁcation using
column chromatography. The stationary phase was made up
of a glass column packed with silica gel 60–200 mesh size.
The mobile phase consisted of combinations of petroleum
ether, chloroform and methanol (MeOH), and the eluting
strength of the solvent was increased gradually by increasing
the composition of the more polar solvent. For puriﬁcation
of the ethanolic extract, the initial solvent composition
was petroleum ether (100% v; 300mL) and then it was
changed to petroleum ether: chloroform (4: 1 v/v; 500mL),
followed by petroleum ether:chloroform (3:2 v/v; 300mL),
petroleum ether:chloroform (2:3 v/v; 200mL), petroleum
ether:chloroform (1:4 v/v; 400mL), chloroform (100% v;
1500mL), chloroform:MeOH (98:2 v/v; 800mL), chlo-
roform:MeOH (95:5 v/v; 1100mL), chloroform:MeOH
(9:1 v/v; 1500mL), chloroform:MeOH (4:1 v/v; 800mL),
chloroform:MeOH (7:3 v/v; 500mL), chloroform:MeOH
(1:1 v/v; 300mL) and ﬁnally to MeOH (100% v; 500mL).
The eluent was collected in fractions of 100mL each. The
chemical composition of each fraction was evaluated by
using thin-layer chromatography (TLC) and visualized with
UV (254 and 365 nm) and iodine vapors. Based on the TLC
proﬁles, fractions with similar compositions were pooled
together and concentrated under reduced pressure. A total
of seven major combined fractions were obtained from the
ethanol extract. A diagram of the puriﬁcation process is
illustrated in Figure 1(a).
The fractions obtained through column chromatography
were subjected to the antiproliferation assay on HeLa cell
line and following that one most active sample (BDF 5)
was selected for evaluation of its antiproliferative eﬀect on
the HeLa cell line. The HPLC of B. diﬀusa fraction 5 (BDF
5) was performed on the Shimadzu HPLC system using
reverse phase C-18 column and UV detector (254 nm).
Methanol:water (50:50; v/v) was used as the mobile phase
and the ﬂow rate was maintained at 1mLmin−1.
2.3. Sample Preparation of B. diﬀus Extract. Boerhaavia
diﬀusa ethanolic root extract and diﬀerent fractions were
dissolved in dimethyl sulfoxide (DMSO, Sigma, St. Louis,
USA). For all experiments, ﬁnal concentrations of the tested
compounds were prepared by diluting the stock with the
culture medium.
2.4. Cell Lines and Culture Medium. HeLa (cervical cancer)
and other cell lines like U-87 (human glioma), Hep 3B
(hepatic cancer), HCT-15 (colon cancer), NIH 3T3 (mouse
embryonic ﬁbroblast) were purchased from NCCS, Pune,
and cultured in Dulbecco’s modiﬁed Eagle medium (Sigma,
St. Louis, USA) supplemented with 10% heat inactivated
fetalbovineserum(GIBCO)and1%penicillin-streptomycin
(Sigma, St. Louis, USA). The cells were incubated in a
humidiﬁed atmosphere of 5% CO2 at 37◦C. All the cell lines
used in the study were of passage number between 5 and 10.
2.5. In Vitro Cytotoxicity Assay. Cell survival was measured
using the MTT microculture tetrazolium assay, according
to the method described by Mosmann [31] with slight
modiﬁcations. Brieﬂy, cells at the exponential growth phase
were trypsinized and resuspended in the complete medium
to a population of 0.25 × 105 cellsmL−1. A total of 5000
cells per well were seeded in a 96-well plate. After 24h
incubation in a 5% humidiﬁed CO2 incubator at 37◦C,
varying concentrations of BD root extract were added
to ﬁnal volume of 200μl of standard growth medium
per well. The concentration of DMSO used to dissolve
the extract did not exceed 0.3% (v/v), and therefore the
same concentration of DMSO was used in control wells.
Methotrexate (at a concentration of 10, 20, 50, 100 and
200nM) was used as a positive control. After 72h incubationEvidence-Based Complementary and Alternative Medicine 3
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Figure 1: Bioactivity-guided puriﬁcation. (a) Bioactivity-guided fractionation on silica gel column chromatography of ethanolic root
extract. (b) Chromatogram of active fraction (BDF 5) resolved using mobile phase methanol:water (50:50) v/v at a ﬂow rate of 1mLmin−1.
at 37◦C, 20μL of MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide] (Invitrogen) 5mgmL−1 in
phosphate buﬀer saline (PBS) was added to each well and
incubated for 4h at 37◦C. The medium was removed and
formazan crystals thus formed were dissolved in DMSO. The
plates were read immediately in a microplate reader (Tecan,
Genios-Pro, Austria) operating at 540nm.
2.6. Cell Proliferation Kinetics. After treatment, cells were
incubated in the growth medium for varying intervals
of time, harvested by trypsinization and counted in a
hemocytometer(adherentandﬂoatingcellspooledtogether)
[32]. Cell proliferation was calculated by computing the
increase in the cell number and the cell proliferation index
P, calculated as
p =
Nt
N0
,
where Nt:n u m b e ro fc e l l sa tt i m et and N0:n u m b e ro fc e l l s
at the time of treatment.
2.7. Morphological Analysis. HeLa cells in the exponential
g r o w t hp h a s ew e r ep l a t e da t2× 104 cells in a 40mm Petri
plate. After 24h growth, cells were treated with BDF 5
(200μgmL −1) and vehicle control for diﬀerent time periods.
At the end of the treatment, the eﬀect of BDF 5 on
morphological change of the HeLa cells was assessed by
the phase-contrast microscope (Nikon, Japan) at 100 ×
magniﬁcation.
2.8.AnalysisofDNAFragmentation. Inamediumcontaining
10% FBS, 0.5 × 106 cells were incubated for 24h. After
24h, cells were treated with BDF 5 at a concentration
of 200μgmL −1. For each experimental time point, cells
were collected by trypsinization and rinsed twice in cold
phosphate buﬀered saline (PBS, pH 7.4). Genomic DNA was
extracted from HeLa cells as described earlier [33]. Brieﬂy
cells were re-suspended twice in a lysis buﬀer containing
1% Nonidet-P40, 20mM EDTA and 50mM Tris-HCl, pH
8. The cells were centrifuged at 1600g for 10min, recovered
supernatant were combined and incubated with 0.5% SDS4 Evidence-Based Complementary and Alternative Medicine
and 0.5mgmL−1 RNase A (Sigma, St. Louis, USA) at 56◦C
for 2h and thereafter treated with 1mgmL−1 Proteinase
K (Bangalore Genei, India) at 37◦C for 4h. The DNA
was precipitated by the addition of 1/10 volume of 7.5M
ammoniumacetateandtwovolumesofethanolandanalyzed
by agarose gel electrophoresis.
2.9. Cell Cycle Analysis. The distribution of cells at diﬀerent
stages in the cell cycle was estimated by ﬂow cytometric
DNA analysis. Flow cytometric measurements of cellular
DNA content were performed with the ethanol (70%)-ﬁxed
cells using the intercalating DNA ﬂuorochrome, propidium
iodide as described by Dwarakanath et al. [34]. Brieﬂy, 5
× 105 cells were incubated overnight in 60mm dishes in a
medium containing 10% FBS. After 24h, cells were treated
with BDF 5 at a ﬁnal concentration of 200μgmL −1.C e l l s
were harvested at diﬀerent time intervals, washed twice with
cold PBS (pH 7.4) and ﬁxed with 70% ethanol/30% PBS
at 4◦C. The ﬁxed cells were washed with PBS to remove
ethanol and incubated with 0.2mL PBS containing RNase
(200μgmL −1) (Sigma, St. Louis, USA) and incubated at
37◦C for 30min, and then stained with 50μgmL −1 propid-
ium iodide (PI, Sigma, St. Louis, MO, USA) for 30min in the
dark at room temperature, and ﬁnally analyzed on a FACS
cytometer (Calibur, Becton Dickinson, USA). A minimum
of 1 × 104 cells per sample was evaluated, and the percentage
of cells in each cell cycle phase was calculated using the
CELLQUEST and Modﬁt software (Becton Dickinson).
2.10. BrdU Pulse Labeling. BDF 5 treated cells were pulsed
with BrdU (a thymidine analogue) (Sigma, St. Louis, USA)
at a concentration of 10μM, 10min before each time point.
After each time point cells were trypsinized and washed
with cold PBS twice, ﬁxed with 70% ethanol and stored at
4◦C until used. The immunoﬂuorescence staining for ﬂow
cytometric analysis was performed as described by Zolzer et
al. [35]. Cells were washed with cold saline (0.9% NaCl), cell
pellet was incubated with pepsin (0.5% in 0.055NHCl, pH
1.8) for 10min at 37◦C. Unwinding of DNA was done with
2N HCl for 30min at room temperature and washed with
PBS. The cells were then incubated with ﬁrst antibody (anti-
BrdU1:300inPBS-Tween)(SantaCruzBiotechnology,Inc.)
for 45min at 4◦C. Non-speciﬁc staining is prevented by ﬁrst
blocking with PBS-Tween 20 (0.05%)–BSA (1%) followed by
incubation with secondary antibody (1:500 in PBS-Tween–
BSA) (Santa Cruz Biotechnology, Inc.) for 45min, at 4◦C.
Cells were then stained with propidium iodide (50μgmL −1).
Cells were ﬁnally acquired by a FACScalibur ﬂow cytometer
(Calibur, Becton Dickinson, USA) and analysis was per-
formed using ModFit software; 10000 events were collected,
corrected for debris and aggregate populations.
2.11. Western Blot Analysis. Following appropriate treat-
ment, cells were detached and collected by centrifugation
(600g, 5min, 4◦C). Whole cell protein was extracted as
described earlier [36]. The pellets were washed with 1mL
of ice-cold PBS, collected again via centrifugation (600g,
5min, 4◦C) and resuspended in a lysis buﬀer containing
25mM HEPES, 5mM MgCl2, 2mM EDTA, 2mM DTT,
1mM PMSF, 1mM sodium orthovanadate, 1% SDS, 1%
Triton X-100 and 1% protease inhibitor cocktail (Sigma, St.
Louis, USA). Lysates of 5 × 106 c e l l sw e r es o n i c a t e da n dt h e n
centrifuged (18000g, 10min, 4◦C). After sonication, lysates
werecentrifugedasabove,andthesupernatantwascollected.
Equal amounts of protein (50μg), as determined using
theBradfordProteinestimationkit(GeNei,BangaloreGenei,
India), were loaded and resolved using 12% SDS-PAGE
and transferred onto PVDF membranes (Mdi, Ambala,
India). Blots were blocked overnight at 4◦C in PBS-Tween
20 (0.05%)–BSA (3%) and then incubated with primary
antibody in the blocking buﬀer (overnight, 4◦C). The
antibodies used in this study included caspase-3, caspase-9
and anti-β-actin. All primary antibodies used were obtained
from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
After washing with PBS containing 0.05% Tween (PBS-T),
blots were incubated with secondary antibody; goat-anti-
mouse IgG-HRP for caspase-9 and donkey-anti-goat IgG-
HRP for caspase-3 and β-actin (Santa Cruz, CA, USA)
f o r2ha t4 ◦C. Following successive washes, the blots were
developed using the DAB system (GeNei, Bangalore Genei,
India). Photographs were taken using GeneSnap acquisition
software (Syngene, Cambridge, UK). GeneTools analysis
software was used for the quantiﬁcation of the bands.
2.12.StatisticalAnalysis. Theexperimentswereperformedin
triplicate and all experimental data were expressed as mean
± SD. The statistical signiﬁcance of the diﬀerence between
control and BD extract-treated groups was determined by
one-way ANOVA followed by Dunnett’s t-tests for multiple
comparisons and Student’s t-test for dual comparison. The
results were considered signiﬁcant at P < .05.
3. Results
3.1. Growth Inhibition of Human Cancer Cell Lines by the
Extracts from B. diﬀusa. Cell lines of diﬀerent origin might
exhibit diﬀerent sensitivities toward the same compound.
Therefore, it was necessary to consider more than one
cell line in the initial screening experiment. Bearing this
in mind, four cell lines of human origin, namely HeLa
(cervical cancer), U-87 (glioma), Hep 3B (hepatic cancer),
HCT-15 (colon cancer) and one mouse NIH 3T3 (mouse
embryonicﬁbroblast),wereusedinthepresentstudy.In vitro
screening of the extract B. diﬀusa indicated that ethanolic
crude root extract is cytotoxic against the HeLa cell line.
Whereas other cell lines namely U-87, HCT-15, Hep 3B
and non-cancerous NIH 3T3 were less sensitive to treatment
by BD EtOH crude root extract (data not shown). At a
concentration of 300μgmL −1, the crude root extract caused
30% cell death in HeLa cell line. The crude extract was
then puriﬁed by column chromatography using silica gel as
stationary phase and increasing the solvent polarity as given
schematically in Figure 1(a). The fractions obtained through
column chromatography were subjected to antiproliferation
assay on HeLa cell line and following that, one most active
sample (BDF 5) was selected for further evaluation of itsEvidence-Based Complementary and Alternative Medicine 5
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Figure 2: Eﬀects of diﬀerent fractions of BD extract on HeLa cells. (a) Cultured cells were exposed to various concentrations of diﬀerent
fractions for 72h. Cell viability was analyzed by MTT assay. #Methotrexate was at a concentration of 10, 20, 50, 100 and 200nM (b) Eﬀects
of BDF 5 on HeLa cells in time- and dose-dependent manner. Cultured cells were exposed to various concentrations of BDF 5 for diﬀerent
time point. Cell viability was analyzed by MTT assay. The result represents the average of three independent experiments in triplicate ± SD.
∗∗P < .01, ∗P < .05.
antiprolirerative eﬀect on this cell line. Fraction 5 (BDF
5) showed maximum cytotoxicity with 85% cell death at
300μgmL −1 in 72h. The HPLC proﬁle of BDF 5 using
a mobile phase (50% methanol:50% water) revealed two
peaks (Figure 1(b)). Characterizations of both of these peaks
are currently under investigation. All other fractions did not
show signiﬁcant antiproliferative eﬀect (Figure 2(a)). The
partially puriﬁed root extract column fraction BDF 5 was
tested in a time- as well as dose-dependent manner for
the cytotoxic eﬀects on HeLa cell line. BDF 5 causes 55%
cell death at a concentration of 300μgmL −1 after exposure
for 24h, while a signiﬁcant eﬀect was not observed at a
concentration of 100μgmL −1. Prolonged treatment (72h)
w i t hB D F5s h o w s8 5 %c e l ld e a t ha tac o n c e n t r a t i o no f
300μgmL −1 and 64% cell death even at a 100μgmL −1
concentration (Figure 2(b)).
3.2. Cell Proliferation. The eﬀects of BDF 5 on the prolifer-
ation of exponentially growing HeLa cells were studied by
monitoring the kinetics of cell growth. A time-dependent
reduction in the rate of cell proliferation was observed
(Figure 3), with a lag period followed by the cytostatic
eﬀect up to 12h and growth inhibition after 24h treatment.
However, almost >50% cells were dead or degenerating at a
concentration of 200μgmL −1 at 48h.
3.3.BDF5CausesVisibleMorphologicalChangesofHeLacells.
We examined morphological changes in the cells in detail
using a phase-contrast microscope. The cells underwent
marked morphologic changes such as shrinkage, rounding,
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Figure 3: Eﬀect of BDF 5 on growth kinetics of HeLa cells. HeLa
cells (5 × 105 cells) in a 60mm culture plate were exposed to
BDF 5 (200μgmL −1)f o rd i ﬀerent time points. Cell number was
measured with trypan blue. The result represents the average of
three independent experiments in triplicate ± SD.6 Evidence-Based Complementary and Alternative Medicine
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Figure 4: Eﬀect of BDF 5 on morphology of the HeLa cells. Morphological changes of cells were examined under phase contrast microscope
at 100x magniﬁcation. (a) Vehicle control cells, (b) BDF 5 (200μgmL −1)-treated cells.
Table 1: Cell cycle distribution of HeLa cell line after treatment with vehicle control (DMSO, 0.3%) or BDF 5 (200μgmL −1).
Distribution (% cells) Control cells BDF 5-treated Cells
24h 48h 72h 24h 48h 72h
G1 52 ± 1.4 60 ± 1.5 59 ± 1.5 48 ± 1.2 54 ± 0.5 47 ± 1.1
G2+M 13 ± 1.5 10 ± 2.1 9 ± 0.6 16 ± 2.0 18 ± 2.1 14 ± 2.0
S3 5 ± 1.6 30 ± 0.5 32 ± 2.0 36 ± 1.8 28 ± 2.5 39 ± 3.1
Sub-G1 1.8 ± 0.3 2.4 ± 0.5 2.4 ± 0.1 15.5 ± 3.5 25 ± 4.0 34 ± 4.1
The data are expressed as mean ± SE from four independent experiments.
detachment and membrane blebbing in HeLa cells exposed
to 200μgmL −1 of BDF 5 for diﬀerent time period (Figure 4).
These morphological changes suggested that BDF 5 may
induce apoptotic cell death in HeLa cells.
3.4. Eﬀe c to fB D F5o nD N AF r a g m e n t a t i o n . DNA fragmen-
tation is a characteristic feature of apoptosis [37]. Therefore,
BDF 5-induced apoptosis was conﬁrmed by the DNA frag-
mentationassay.IncreasedDNAfragmentationwasapparent
in HeLa cells after treatment with 200μgmL −1 of BDF 5
for 24, 48 and 72h. A typical experimental result of agarose
gel electrophoresis is shown in Figure 5, where the eﬀect of
BDF 5 for 72h treatment produced DNA fragmentation.
Whereas treatment with DMSO (0.3%) (negative control)
did not produce DNA fragment ladders after 72h in HeLa
cells. Treatment with methotrexate (positive control) at a
200nM concentration also produced DNA fragment ladders
after 72h treatment in HeLa cells.
3.5. Cell Cycle Perturbations. The eﬀect of partially puriﬁed
fraction on cell cycle progression of HeLa cells was deter-
mined by ﬂow cytometry. HeLa cells treated with BDF 5 at
a ﬁnal concentration of 200μgmL −1 showed decrease in G1
phase cells from 52 ± 1.4% to 48 ± 1.2% and this decrease in
the G1 phase was accompanied by increase in the population
of the G2+M phase from 13 ± 1.5% in control to 16 ± 2.0%
in treated cells. BDF 5 also showed moderate inhibition in
the progression through the S-phase, with a slight decrease
in the population of the S-phase from 30 ± 0.5% to 28 ±
2.5% at 48h. This was accompanied by an increase in the
population of the G2+M phase from 10 ± 2.0% in control to
18 ± 2.0% in the treated cultures. After 72h, treatment cells
get accumulated in the S-phase as well as there is increase
in the population of G2+M cells. This was accompanied by
a decrease in the proportion of cells in the G1 phase of cell
cycle (Table 1). A representative histogram for the HeLa cells
is shown in Figure 6.Evidence-Based Complementary and Alternative Medicine 7
MTX C 24h 48h 72h
Figure 5: DNA fragmentation in BDF 5-treated HeLa cells.
Genomic DNA was extracted from DMSO (0.3%) and BDF 5
(200μgmL −1)-treated HeLa cells after incubation for 24, 48 or 72h.
Nucleosomal DNA fragments were resolved by electrophoresis in a
1.5% agarose gel and visualized by ethidium bromide staining. C,
DMSO control; MTX, methotrexate at a concentration of 200nM.
From cell cycle analysis we observed the appearance of
a peak corresponding to a population of cells with sub-G1
DNA content after 48h treatment. The DNA histograms
revealed a hypo-diploid population after 48h treatment
(Figure 6), suggestive of apoptotic cell death under these
conditions.
3.6. Determination of S-Phase Cells Using Bromodeoxy Uri-
dine. To investigate the cells in the S-phase of cell cycle
BrdU pulse labeling was performed, the inhibitory eﬀect of
fraction 5 (BDF 5) on HeLa cell line was further conﬁrmed
using BrdU incorporation into the untreated and treated
cells in vitro. The eﬀect of BDF 5 on DNA synthesis was
thus investigated by measuring BrdU incorporaton by ﬂow
cytometry with an anti-BrdU primary monoclonal antibody.
Biparametric histograms of BrdU-FITC ﬂuorescence verses
PI ﬂuorescence is shown in Figure 7. BrdU-labeled cells in
the untreated HeLa cells was 94.09 ± 3.97%, while after 48h
treatment with 200μgmL −1 of BDF 5, BrdU-labeled cells
were60.75 ±1.88%.Thiscomesouttobe17%ofatotal28%
S-phase cells as determined by cell cycle analysis. Statistical
signiﬁcances were found in untreated and treated cells (P <
.01).
3.7. BDF 5-Induced Diﬀerential Caspases Proteins Expression
Related to Apoptosis in HeLa Cells. In order to assess the
mechanism of BDF 5-induced apoptosis, we evaluated
the expressions of caspases by the western blot analysis.
Caspases are cytosolic proteins that exist normally as inactive
precursors with higher molecular weight (46, 32kDa). They
are cleaved proteolytically into low molecular weights (20–
23kDa) when cell undergo apoptosis [38]. In this study, the
expressions of the inactive form of caspase-3 and caspase-
9 declined after treatment with BDF 5 (200μgmL −1)a t
diﬀerent time periods (Figure 8(a)). Approximately 50%
fall in the expression of procaspase-9 and 25% fall in the
expression of procaspase-3 in comparison to control after
48h treatment (Figures 8(b) and 8(c)).
4. Discussion
The treatment of cancer may beneﬁt from the introduction
of novel therapies derived from natural products. Natural
products have served to provide a basis for many of the
pharmaceutical agents in current use in cancer therapy
[39]. The root, leaves and aerial parts or the whole plant
of B. diﬀusa have been employed for the treatment of
various disorders in the Ayurvedic herbal medicine. It was
evidenced that the leaves and root possessed antiﬁbrinolitic
and anti-inﬂammatory activities [11]. Ethanolic extracts
were normally used for anticancer screening because cir-
cumstantialevidencesfromtraditionalpractitionersbelieved
that mostly the polar compounds are responsible for the
claimed anticancer properties. The study, by Mehrotra et al.
reported that the ethanolic extract of B. diﬀusa showed a
signiﬁcant antiproliferative and immunosuppressive activity
[17]. Taking lead from these we have started our work with
ethanolic extract. Leyon et al. showed the inhibitory eﬀect
of B. diﬀusa on experimental metastasis [20]. The present
study was conducted to study the cytotoxicity activity of
BD EtOH root extract as well as its puriﬁed fraction (BDF
5) on HeLa cell line to provide an introductory approach
for the evaluation of its traditional preparation in order
to scientiﬁcally validate the therapeutic preparation of this
plant in the control of cancer. To the best of our knowledge,
this is the ﬁrst report that analyzes the inhibitory eﬀect of
BDF 5 on the S-phase of cell cycle in HeLa cell line. Cell
lines of diﬀerent histological origin might exhibit diﬀerent
sensitivities toward an antiproliferative compound. Cell type
antiproliferative speciﬁcity is observed in B. diﬀusa ethanolic
crude root extract. It showed cytotoxicity against the HeLa
cell line and was less toxic to the other cell lines tested.
This speciﬁcity of plant extracts is likely to be due to the
presence of diﬀerent classes of compounds in the extract,
as it has been documented in the case of known classes of
compounds [40]. The plant ethanolic extract was fraction-
ated on silica gel column chromatography, according to the
compound polarity. These were subjected to the MTT test
forantiproliferativeactivity(Figure 2(a)).TheBDF5showed
the cytotoxicity against the HeLa cell line with the IC50
valuesof250μgmL −1 at48h(Figure 2(b)).Suchobservation
d e m o n s t r a t e dt h a ts o m ea c t i v ec o m p o n e n t so ft h i sp l a n t
should be in the chloroform:methanol fraction. However,
the antiproliferative activities of this plant might be possibly
dependent on cell types including the culture conditions. In
thisstudy,theresultsofcellviabilityassayandmorphological
analyses showed that BDF 5 signiﬁcantly inhibited HeLa cells
proliferation in a time-dependent manner (Figures 3 and 4).8 Evidence-Based Complementary and Alternative Medicine
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Figure 6: Cell cycle analysis of HeLa cells after treatment with vehicle control (0.3% DMSO) or 200μgmL −1 B D F5 .C e l l sw e r ec o l l e c t e da n d
processed for cytometric analysis of cell cycle distribution. DNA content was analyzed using PI staining and DNA ﬂow cytometry. (a) Cells
were treated with vehicle (0.3% DMSO). (b) Cells were treated with BDF 5 (200μgmL −1)f o rd i ﬀerent time points.
The antiproliferative activity of BDF 5 on HeLa cells might
result, at least in part, from inhibition of DNA synthesis and
proliferation, and from induction of apoptosis (Figure 6).
Observations from ﬂow cytometric DNA analysis suggests
that the mode of cell death induced by BDF 5 is mainly
through apoptosis, culminating in secondary necrosis. This
has been further strengthened by the DNA fragmentation
assay (chromatin fragmentation by internucleosomal DNA
cleavage), which is considered a hallmark of apoptosis.
The appearance of a DNA ladder was investigated by
agarose gel electrophoresis of genomic DNA extracted from
DMSO (0.3%)—or BDF 5 (200μgmL −1)-treated HeLa cells.
BDF 5-treated cells showed typical internucleosomal DNA
fragmentation or “ladder” formation at all time points
tested (Figure 5). Cell proliferation kinetics clearly showed
that 200μgmL −1 retarded the rate of progression through
the S-phase and induced an accumulation of cells in
G2+M (Table 1). Although, retarded, it appears that the
completionoftheS-phasewasachievable,butthepersistence
of the lesions probably prevented cells from undergoing
mitosis, thus blocking the cells at G2–M transition through
G2 checkpoint control. Inhibition of DNA synthesis and
therefore progression through the cell cycle of HeLa cells
was conﬁrmed by the reduced BrdU incorporation that
correlated well with decreased cell proliferation. BrdU is a
thymidine analog that is incorporated in place of thymidine
into synthesized DNA strands of actively proliferating cells.
Incorporation of BrdU is therefore used as evidence of
DNA replication. The ability of BDF 5 to reduce the
incorporation of BrdU into DNA can thus be interpreted
as the ability of BDF 5 to inhibit DNA synthesis. After
treatment with 200μgmL −1 BDF 5 for 48h, proliferation
of BrdU-labeled cells was reduced signiﬁcantly (P < .01)
(Figure 7), which indicated that BDF 5 extract aﬀected the
proliferation of cervical cancer cells through inhibition of
DNA synthesis. Although treatment with BDF 5 did not
signiﬁcantly alter the fraction of S-phase cells as analyzed
by DNA analysis (Table 1), it did not rule out the inhibitory
eﬀect of BDF 5 on the progression of DNA synthesis
(chain elongation) as analysis of DNA content alone does
not discriminate between cells in S-phase (based on DNA
content) that are actively synthesizing DNA (S +ve) from
quiescent S-phase cells (not engaged in DNA synthesis; S
−ve or S0 cells). Treatments like certain chemotherapeutic
drugs and high doses of radiation are well known to arrest
cells also in the S-phase and thereby result in growthEvidence-Based Complementary and Alternative Medicine 9
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Figure 7: DNA synthesis in untreated HeLa cells and cells treated with BDF 5. Cells were treated with BDF 5 (200μgmL −1)f o rd i ﬀerent
time point and pulsed with BrdU. Incorporation of BrdU was detected by immunoﬂuorescence using a BrdU monoclonal antibody. The
DNA content, measured by propidium iodide staining of cells, is represented as a linear scale on the abscissa, showing cells with 2N or 4N,
respectively, in G1 (lower left of each panel) and G2/M (lower right of each panel). The ordinate is a logarithmic scale representing cells
in S-phase, based on incorporation of 5-bromodeoxyuridine. (a) Cells were treated with vehicle (0.3% DMSO). (b) Cells were treated with
BDF 5 (200μgmL −1)f o rd i ﬀerent time points. (c) Graphical representation of BrdU positive cells in control and BDF 5-treated cells. The
data are expressed as mean ± SD from three independent experiments. ∗∗P < .01.10 Evidence-Based Complementary and Alternative Medicine
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Figure 8: BDF 5-induced apoptotic cell death in HeLa cells. Culture cells were treated with vehicle control (0.3% DMSO) or with BDF 5
at a concentration of 200μgmL −1 for diﬀerent time periods. After incubation the cells were lysed and the cellular proteins were separated
by SDS-polyacrylamide gels and transferred onto PVDF membranes. Procaspase-9 (46kDa) and procaspase-3 (32kDa)-speciﬁc bands were
detected by western blot. Immunoblot represents the observations from one single experiment repeated three times (a). The integrated
optical densities (IOD) of caspase-9 and -3 proteins after normalization with β-actin (43kDa) in each lane using GeneTools analysis
software (Syngene) were demonstrated in (b) and (c), respectively. Each data point in the ﬁgure represents the mean ± SD of three separate
experiments. Statistical diﬀerence compared to control. ∗P < .05, ∗∗P < .01.
inhibition. It is possible to discriminate the S +ve from
S −ve only with the help of probes that identify cells
actively synthesizing DNA; for example the incorporation
of radiolabeled thymidine (and counting the radioactivity)
or BrdU coupled with anti-BrdU antibody and analysis by
ﬂow cytometry. We chose to use the BrdU method. The
BrdU pulse labeling experiment measures the fraction of
cells which are actively involved in DNA synthesis out of the
total S-phase cells. Cell cycle analysis revealed that 48h after
treatment with BDF 5, 28% of the total cells were in the S-
phase (as compared to 30% in untreated cultures). Nearly
60%oftheseS-phasecells(i.e., ∼17%ofthetotalcells)tested
+ve to BrdU incorporation (S +ve cells) suggesting that they
were actively involved in DNA synthesis, while the remaining
40% (i.e., 11% of the total population) were quiescent in S-
phase (S −ve).
The activation of cystein aspartic-speciﬁc proteases
(caspases) is commonly thought to be one of the earliest
points in the no-return pathway of apoptosis. Caspases are
broadly categorized into upstream regulatory caspases and
downstream eﬀector caspases [41]. The upstream caspases,
such as caspase-8 (death receptor pathway) and caspase-9
(mitochondria pathway), typically have a long N-terminal
prodomain that facilitates interaction with and recruitment
of proapoptotic proteins, including other caspases [42]. The
downstream caspases, such as caspase-3, -6 and -7, typically
haveshortprodomainsthatprimarilycleaveprotein,whichis
important for cellular functions, and results in cell apoptosis
[43, 44]. Our results indicated that apoptotic signaling
triggered by BDF 5 is mainly related to the mitochondrial
pathway. We determined whether caspase-9 and caspase-3
might be activated during the induction of apoptosis by
BDF 5 because caspase-3 is known to play an essential
role as an executor in apoptosis. We observed decrease
in the expression level of a 46kDa precursor (procaspase-
9) and a 32-kDa precursor (procaspase-3) after treatmentEvidence-Based Complementary and Alternative Medicine 11
Boerhaavia diﬀusa
BDF 5
BDF 5 Apoptosis
Caspase-3
Caspase-9
S-phase inhibition
Cell cycle
S
G1
G2
M
Figure 9: An overview of apoptotic eﬀects elicited by B. diﬀusa fraction 5 (BDF 5) on HeLa cells. S-phase inhibition plays some roles in BDF
5-induced antiproliferative activities. The apoptotic mechanism was mediated by the activation of caspase-9 (upstream regulatory caspase)
and caspase-3 (downstream eﬀector caspase). Thiswas subsequentlyresultinginbiochemical and morphological alterations, includingDNA
fragmentation, membrane blebbing and formation of apoptotic bodies.
indicating that caspase-9 and caspase-3 were activated by
BDF 5 (Figure 8). These results demonstrate conclusively
that BDF 5 induces apoptosis in HeLa cells, accompanying
by the triggered caspase-9 and caspase-3 activation.
Therefore, it could be concluded that the anti-prolife-
rative activity of BDF 5 might result, at least in part, from
inhibition of DNA synthesis, retardation of cell proliferation
and induction of apoptotic death of cancer cells. Many
anticancer drugs inhibit cell cycle progression. These are
exempliﬁed by compounds that (i) interfere with nucleotide
metabolism, such as methotrexate, which inhibits dihy-
drofolate reductase; (ii) damage the DNA, for instance,
anthracyclins, topoisomerase inhibitors, or alkylating agents;
or (iii) prevent the formation of a functional mitotic
spindle, such as the taxanes or vinca alkaloids. All of these
perturbations cause some kind of damage to the cell, leading
to the activation of speciﬁc checkpoints that trigger cell
death [45]. Various drugs [1-β-d-arabinofuranosylcytosine
(ara-C), hydroxyurea (HU), 5-hydroxy-2-formylpyridine
thiosemicarbazone (5-HP) and camptothecin sodium salt
(camptothecin)] considered to markedly inhibit DNA syn-
thesis and are maximally cytotoxic to cells in the S-phase
[46]. A phase-speciﬁc agent will be maximally eﬀective only
if it allows cycling cells to enter the cytotoxic phase. Thus,
a S-phase-speciﬁc agent that blocks the progression of G1
cells into S will kill only those cells that are in S at the
time the drug is added. Sinclair showed that HU2 has such
an eﬀect, namely the cells in the S-phase are killed, while
the non-S-phase cells accumulate at the G1-S boundary [47,
48]. When HU is removed, the accumulated cells proceed
synchronously through the cell cycle. Ara-C has been shown
to have similar eﬀects [49]. Inhibition of DNA synthesis
could be caused by incorporation of the molecule into DNA,
as is the case for Ara-C and dFdC. More likely, it is possible
that BDF 5 directly inhibits DNA polymerases or binds
to DNA in a non-intercalative mode, thereby interfering
with DNA chain elongation. These possibilities are currently
under investigation.
5. Conclusion
In conclusion, B. diﬀusa fraction 5 (BDF 5) could inhibit
the proliferation of human cervical cancer cell line, HeLa.
Our results demonstrated that the cell cycle via S-phase
inhibition plays some roles in B. diﬀusa-induced antiprolif-
erative activities in the HeLa cell line. Taken together, the
ﬁndings of this study are schematically presented in Figure 9.
The alcoholic and water extracts of B. diﬀusa is known
to contain several bioactive molecules such as reducing
sugars, starch and lignans liriodendrin and syrigaresinol.
Several Boeravionones (Boeravionones A–J, etc.) have also
been isolated from B. diﬀusa. The activity shown by the
partially puriﬁed fraction 5 (BDF 5) may be attributed
to these diverse compounds. Although scientiﬁc studies
have been done on a large number of Indian botanicals,
a considerably smaller number of marketable drugs of
phytochemical entities have entered the evidence-based
therapeutics [50]. The authors would like to ascertain that
B. diﬀusa is a promising drug entity which should enter the
world market by evidence-based research for therapeutics.
However, further biochemical work and investigations at the
molecular level are currently under progress in our labo-
ratory to identify the active components that could induce
growth inhibition and to establish the possible explanation
of mechanism of DNA synthesis inhibition by the herb
extract.12 Evidence-Based Complementary and Alternative Medicine
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